Your browser is no longer supported. Please, upgrade your browser.
NVO [NYSE]
Novo Nordisk A/S
Index- P/E31.42 EPS (ttm)3.04 Insider Own26.40% Shs Outstand2.29B Perf Week-0.91%
Market Cap172.10B Forward P/E4.47 EPS next Y21.33 Insider Trans0.00% Shs Float1.11B Perf Month-13.16%
Income7.02B PEG2.64 EPS next Q4.64 Inst Own7.80% Short Float0.25% Perf Quarter-9.97%
Sales20.46B P/S8.41 EPS this Y10.00% Inst Trans0.20% Short Ratio2.21 Perf Half Y6.91%
Book/sh4.38 P/B21.79 EPS next Y3.10% ROA29.90% Target Price116.90 Perf Year30.42%
Cash/sh2.98 P/C32.00 EPS next 5Y11.90% ROE72.90% 52W Range66.59 - 117.35 Perf YTD-14.79%
Dividend1.47 P/FCF36.68 EPS past 5Y5.90% ROI58.50% 52W High-18.81% Beta0.54
Dividend %1.54% Quick Ratio0.80 Sales past 5Y3.30% Gross Margin82.90% 52W Low43.08% ATR2.84
Employees46982 Current Ratio1.00 Sales Q/Q15.20% Oper. Margin41.70% RSI (14)29.06 Volatility2.34% 2.02%
OptionableYes Debt/Eq0.21 EPS Q/Q19.60% Profit Margin34.30% Rel Volume1.93 Prev Close95.44
ShortableYes LT Debt/Eq0.19 Earnings- Payout293.00% Avg Volume1.27M Price95.28
Recom2.00 SMA20-7.42% SMA50-11.56% SMA200-0.21% Volume2,267,051 Change-0.17%
Jan-25-22Downgrade Liberum Hold → Sell
Dec-20-21Downgrade JP Morgan Overweight → Neutral
Dec-17-21Downgrade Deutsche Bank Buy → Hold
Jan-20-21Downgrade Credit Suisse Outperform → Neutral
Jan-15-21Initiated Deutsche Bank Buy
Sep-29-20Initiated Berenberg Hold
Jul-06-20Downgrade BofA Securities Buy → Neutral
May-11-20Downgrade UBS Buy → Neutral
May-04-20Initiated Cowen Market Perform $72
Mar-16-20Upgrade BofA/Merrill Neutral → Buy
Jan-03-20Downgrade Guggenheim Buy → Neutral
Nov-18-19Upgrade Barclays Equal Weight → Overweight
Sep-17-19Upgrade Citigroup Neutral → Buy
Aug-30-19Downgrade Jefferies Hold → Underperform
Jun-20-19Downgrade Deutsche Bank Buy → Hold
Jun-11-19Upgrade Barclays Underweight → Equal Weight
Apr-29-19Upgrade Credit Suisse Neutral → Outperform
Jan-29-19Initiated Exane BNP Paribas Outperform
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Jan-25-22 09:38AM  
Jan-24-22 01:38PM  
09:30AM  
Jan-19-22 05:38PM  
05:38PM  
Jan-18-22 01:38PM  
Jan-17-22 11:28AM  
Jan-14-22 01:38PM  
11:14AM  
08:48AM  
07:09AM  
Jan-11-22 01:38PM  
10:04AM  
Jan-10-22 08:23AM  
Jan-07-22 06:00AM  
Jan-05-22 01:38PM  
Dec-27-21 11:38PM  
Dec-22-21 09:29AM  
Dec-20-21 11:40AM  
08:57AM  
03:12AM  
03:02AM  
02:39AM  
Dec-17-21 12:18PM  
07:52AM  
Dec-14-21 05:55PM  
Dec-13-21 10:49AM  
07:49AM  
Dec-12-21 11:34PM  
Dec-10-21 01:34PM  
08:34AM  
08:30AM  
Dec-09-21 07:02AM  
Dec-08-21 02:31PM  
Dec-07-21 09:50AM  
06:20AM  
Dec-06-21 07:29AM  
Dec-03-21 11:40AM  
Dec-02-21 08:18AM  
Nov-29-21 10:19AM  
Nov-26-21 01:06AM  
Nov-23-21 06:23AM  
Nov-22-21 09:09AM  
Nov-19-21 11:15PM  
10:03AM  
Nov-18-21 04:21PM  
02:16PM  
12:43PM  
11:38AM  
10:29AM  
10:10AM  
09:28AM  
07:28AM  
07:20AM  
07:19AM  
07:19AM  
05:10AM  
04:02AM  
Nov-17-21 12:04PM  
11:40AM  
09:58AM  
Nov-16-21 04:07PM  
Nov-15-21 11:00AM  
08:42AM  
Nov-12-21 10:50AM  
08:06AM  
07:40AM  
05:57AM  
Nov-11-21 02:14PM  
10:53AM  
Nov-09-21 11:06PM  
Nov-08-21 07:03AM  
Nov-05-21 05:02PM  
04:55PM  
04:50PM  
08:59AM  
08:47AM  
08:45AM  
Nov-04-21 10:21AM  
Nov-03-21 06:30PM  
01:21PM  
10:00AM  
03:14AM  
02:43AM  
02:30AM  
Nov-02-21 07:39AM  
06:02AM  
Oct-29-21 02:29PM  
09:04AM  
Oct-26-21 02:04PM  
10:45AM  
Oct-25-21 04:32AM  
Oct-21-21 09:25AM  
Oct-18-21 09:34AM  
Oct-14-21 11:40AM  
Oct-11-21 08:55AM  
Oct-06-21 02:27PM  
Oct-04-21 10:29AM  
Oct-01-21 09:23AM  
Sep-30-21 10:47AM  
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.